Insider Selling: Myriad Genetics, Inc. (NASDAQ:MYGN) EVP Sells $295,600.00 in Stock
Myriad Genetics, Inc. (NASDAQ:MYGN) EVP Paul Parkinson sold 11,824 shares of Myriad Genetics stock in a transaction dated Friday, January 8th. The stock was sold at an average price of $25.00, for a total value of $295,600.00. Following the completion of the transaction, the executive vice president now owns 76,746 shares of the company’s stock, valued at $1,918,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of MYGN stock opened at $24.82 on Thursday. The firm has a market capitalization of $1.87 billion, a PE ratio of -9.55 and a beta of 1.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.75 and a current ratio of 2.95. Myriad Genetics, Inc. has a 1 year low of $9.24 and a 1 year high of $30.13. The stock has a fifty day moving average of $19.65 and a two-hundred day moving average of $14.85.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.15. The business had revenue of $145.20 million for the quarter, compared to analysts’ expectations of $134.59 million. Myriad Genetics had a negative net margin of 32.49% and a negative return on equity of 4.07%. The company’s revenue was down 22.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.08 earnings per share. Equities research analysts predict that Myriad Genetics, Inc. will post -0.57 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the company. California State Teachers Retirement System grew its position in shares of Myriad Genetics by 1.3% in the second quarter. California State Teachers Retirement System now owns 108,819 shares of the company’s stock valued at $1,234,000 after purchasing an additional 1,405 shares during the last quarter. American International Group Inc. increased its stake in shares of Myriad Genetics by 2.9% in the second quarter. American International Group Inc. now owns 50,673 shares of the company’s stock valued at $575,000 after buying an additional 1,442 shares in the last quarter. Swiss National Bank raised its holdings in shares of Myriad Genetics by 1.6% in the third quarter. Swiss National Bank now owns 169,000 shares of the company’s stock valued at $2,204,000 after buying an additional 2,600 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Myriad Genetics by 3.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 81,293 shares of the company’s stock worth $1,060,000 after buying an additional 2,718 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in Myriad Genetics by 14.7% during the 2nd quarter. Stifel Financial Corp now owns 26,747 shares of the company’s stock worth $303,000 after acquiring an additional 3,424 shares during the last quarter. 91.06% of the stock is owned by institutional investors.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool.
Featured Story: What is meant by a buy rating?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.